Leerink Not Surprised by CEO Change at Endo Int'l (ENDP); Affirms at 'Market Perform'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Oppenheimer Remains Sidelined Following Endo Int'l's (ENDP) New CEO Appointment
September 26, 2016 10:04 AM EDTOppenheimer reiterated a Perform rating on Endo International plc (NASDAQ: ENDP), following the company's announced appointment of Paul Campanelli to president and chief executive officer. Mr. Campanelli joined ENDP in 2015 through the acquisition of Par Pharmaceuticals and most recently served as the CEO of Par. Mr. Campanelli's... More
Piper Jaffray Reiterates Neutral as Endo Int'l (ENDP) Announces Paul Campanelli as New CEO
September 26, 2016 8:26 AM EDTPiper Jaffray reiterated a Neutral rating and $19.00 price target on Endo International plc (NASDAQ: ENDP) following the company's announcement appointment of Paul Campanelli as CEO effective immediately. Mr. Campanelli was responsible for the 2014 acquisition of JHP Pharma, which gave Par a sizable generic injectibles business and more importantly gave the... More
Janney Montgomery Scott Upgrades BioDelivery Sciences International (BDSI) to Buy
September 23, 2016 7:25 AM EDTJanney Montgomery Scott upgraded BioDelivery Sciences International (NASDAQ: BDSI) from Neutral to Buy with a price target of $4.00 as Belbuca will be added as the preferred brand over Butrant on United Healthcare Formulary.
Analyst Ken Trbovich commented, "Endo International plc (NASDAQ:... More
Endo Int'l (ENDP) CEO De Silva Resigns; New CEO Appointed; Guidance Reaffirmed
September 23, 2016 7:03 AM EDTEndo International plc (Nasdaq: ENDP) announced that its Board of Directors has named Paul V. Campanelli President and Chief Executive Officer, effective immediately. Mr. Campanelli currently serves as President of Endo's Generic and OTC drugs business, Par Pharmaceutical, which accounts for approximately 60 percent of Endo's total revenues through the first half of 2016. Campanelli, who will also join Endo's Board of Directors, succeeds Rajiv De Silva, who has stepped down as President, CEO and a member of the Board.
Campanelli, 54, joined Endo in 2015 following Endo's acquisition of Par Pharmaceutical, where he had served as... More
